Invivyd Says Pemivibart Confers 84% Reduction In COVID-19 Risk, To Engage FDA With Expedited Pathway
21/5 18:32
(RTTNews) - Invivyd, Inc. (IVVD), a biopharmaceutical company, Wednesday announced that during its CANOPY phase 3 trial Pemivibart conferred an 84 percent reduction in the risk of becoming sick from COVID-19, compared to placebo. The formal evaluation was for six months, with a f...